Intrinsically resistant leukemia cells (e.g., stem cells) have a constitutively activated NFκB pathway and the combination of BTZ with NFκB inhibition by the IKK inhibitor BMS-345541, enhanced the kill of AML stem cells [99]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.